PRZOOM - /newswire/ -
Philadelphia, PA, United States, 2009/08/27 - ERT, a leading provider of centralized ECG, ePRO and other services to the biopharmaceutical, medical device and related industries, announced the appointment of a new Associate Director of Business Development - Japan, Miki Stevens.
Ms. Stevens will report to the Senior Vice President of Strategic Marketing, Planning and Partnerships. In this new role, Ms. Stevens will work with ERT's Japanese partner, Site Support Institute (SSI) to facilitate sales activities and enhanced in-country support of Japanese sponsors and clinical trial sites. By nurturing existing strategic partnerships, Ms Stevens will contribute to increase ERT's Japan-based and other Far Eastern sales, supporting the demands of customers worldwide.
Ms. Stevens has dual Japanese and American citizenships and speaks and writes fluent Japanese and English. She has a Bachelor of Arts degree from Tufts University (Boston) and has built up extensive project management and business development experience, including timeline management, budgeting resource allocation and marketing strategy. Ms. Stevens will assist in all aspects of developing and executing Japanese and other regional Asian strategic initiatives and partnerships working in collaboration with ERT sales, operations and other relevant departments.
Ms Stevens joins ERT from PAREXEL International Inc. (Tokyo) where she worked as an Account Manager in Business Development. In this role, Ms. Stevens managed relations with biopharmaceutical and medical device clients and successfully launched the marketing department. She previously served as a Senior Clinical Research Associate for Ophthalmic Research Associates (Massachusetts, USA), where she was project leader of clinical trials.
ERT has established relationships with more than 24 strategic alliances and partners worldwide that offer its clients seamless integration points across their clinical trial needs. ERT's focus ensures continued innovation and growth in order to build strategic initiatives and strong partnerships.
Robert Brown, SVP, Strategic Marketing, Planning and Partnerships at ERT, comments, "We are delighted to welcome Miki to the ERT team. This new appointment continues our investment in the Japanese and wider Pacific Rim markets helping us to expand our direct sales reach and service the needs of our clients in the best possible way. We strongly believe this appointment will further improve and enhance the quality of our services in this market."
Robert added, "With Miki's experience and exceptional language skills, we are confident she will be a key member of our business development team. With this new appointment we are demonstrating our commitment to providing tailored solutions for clinical trials in order to meet the demands of customers from all around the world."
ERT is a leading provider of technology and services to the biopharmaceutical and medical device industries around the world. The key areas of ERT products and services - ERT Cardiac Safety Solutions, ERT ePRO Solutions and ERT Clinical Research Consulting Group - are all enabled by the Company's innovative technology platform - EXPERT. EXPERT is a robust, secure and validated clinical research workflow-processing system that powers centralized electronic data collection, data management and information exchange.
For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. P: +44 1477 539539, F: +44 1477 539540, E: ert[.]scottpr.co.uk
Based in Philadelphia, PA, ERT (eResearchTechnology, Inc.) is a provider of technology and services to the global biopharmaceutical and medical device industries. The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company also provides technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2009 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.